An intravenous malaria vaccine was found effective in a small clinical trial. Maryland-based biotech company Sanaria developed the PfSPZ vaccine made from sporozoites, an immature stage of malarial parasite Plasmodium falciparum. A study in the journal Science reported that among the 15 participants who were administered high doses of the vaccine, 12 have shown complete immunity from the infectious disease. However, administering the intravenous vaccine may be challenging in a larger scale, compared with injected and oral vaccine that are given promptly.
Published in Brief: